H2 beat; 2026 outlook healthy; but valuation remains red-hot
26/02/26 -"The H2 25 results exceeded the consensus, and the 2026 guidance (CER) was better than the consensus estimates at AER. The H2 performance was driven by UCB’s five key drugs, and the older ..."
Pages
49
Language
English
Published on
26/02/26
You may also be interested by these reports :
27/02/26
The Q4 results were ahead of consensus, but a lack of 2026 sales guidance casts doubt over Grifols’ ability to deliver on its 2029 sales and ...
27/02/26
The Q4 sales exceeded expectations, though ‘adjusted’ EBITDA was somewhat behind the consensus. The Q4 performance was driven by LatAm, Animal ...
26/02/26
Even though the H2 25 results were ahead of consensus, the 2026 outlook was below the street’s expectations. While Branded posted strong H2 growth, ...
26/02/26
Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the ...